Initiating breast cancer by PIK3CA mutation

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Miller, Todd W ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110; PROTEIN P85; SHORT HAIRPIN RNA; PIK3CA PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG WITHDRAWAL; ENZYME INHIBITION; EXON; GAIN OF FUNCTION MUTATION; GENE; GENE AMPLIFICATION; GENE SILENCING; INTRACELLULAR SIGNALING; INTRADUCTAL CARCINOMA; NONHUMAN; PIK3CA GENE; TUMOR REGRESSION; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; MISSENSE MUTATION; PAGET NIPPLE DISEASE; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MUTATION, MISSENSE; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84856774967     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3103     Document Type: Article

References (10)

1. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011, 13:224. 10.1186/bcr3039, 22114931.
2. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644. 10.1038/nrd2926, 3142564, 19644473.
3. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65:2554-2559. 10.1158/0008-5472-CAN-04-3913, 15805248.
4. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007, 317:239-242. 10.1126/science.1135394, 17626883.
5. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008, 105:2652-2657. 10.1073/pnas.0712169105, 2268191, 18268322.
6. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann SM, Fritsch C, Dorsch M, Chene P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson C, Schlegel R, Hofmann F, Garcia-Echeverria C, Sellers WR, Voliva CF. Identification and characterization of NVP-BKM120, an orally available pan class I PI3-Kinase inhibitor. Mol Cancer Ther 2011, [Epub ahead of print].
7. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 2008, 3:e3065. 10.1371/journal.pone.0003065, 2516933, 18725974.
8. Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010, 70:5674-5678. 10.1158/0008-5472.CAN-08-2660, 2905503, 20551053.
9. Meyer DS, Brinkhaus H, Muller U, Muller M, Cardiff RD, Bentires-Alj M. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res 2011, 71:4344-4351. 10.1158/0008-5472.CAN-10-3827, 21482677.
10. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, Zhao JJ. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 2011, 17:1116-1120. 10.1038/nm.2402, 21822287.